Dr. Liu Lu - CML - Chronic myeloid leukemia
PhD (Medicine), The University of Adelaide
Bachelor of Health Science (Hons), The University of Adelaide
Research FocusCurrently approved tyrosine kinase inhibitors (TKIs; imatinib, nilotinib and dasatinib) are the main course of treatment for chronic myeloid leukaemia (CML). However, diverse TKI resistance mechanisms cause a proportion of patients to fail therapy. Identified resistance mechanisms in CML patients include Bcr-Abl kinase domain mutations, increasedBCR-ABL1 expression, and increased drug-efflux or decreased drug-influx. Ponatinib, a novel third generation TKI, has recently been demonstrated to successfully overcome mutation-based, especially T315I-based, resistance in a cellular screen. Dr Lu's study focuses on investigating the cellular transport of ponatinib, which may mediate the development of ponatinib resistance, and identifying other potential ponatinib resistance mechanisms by generating and characterising ponatinib resistant CML cell lines. Dr Liu Lu's study also aims to determine the efficacy of ponatinib in different mutation settings, and therefore facilitates future TKI design.
Extract of sahmriresearch.org